• 1
    Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387.
  • 2
    Katz L, Paul M, Guy D, Leibovici L, Tur-Kaspa R. Prevention of recurrent hepatitis B virus infection after liver transplantaiton. HBIG antiviral drugs or both? Systematic review and meta analysis. Hepatology 2008; 48: 573A.
  • 3
    Degetekin B, Luketic V, Schiff ER, et al. Hepatitis B immune globulin regimens used in US liver translant centres and relationship to HBV replication status pre OLT and recurrence. Hepatology 2008; 48: 311A.
  • 4
    Lenci I, Tisone G, Di Paolo D, et al. Total and covalently closed circular DNA detection in post liver transplant liver biopsies of HBV positive patients who underwent liver transplantation with undetectable viraemia. Hepatology 2008; 44: 573A.
  • 5
    Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus ‘e-minus’ patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17: 783.
  • 6
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266.
  • 7
    Van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318.
  • 8
    Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001.
  • 9
    Angelico M, Di Paolo D, Lenci I, et al. One year extended anti-HBV vaccination with an MPL adjuvanted vaccine combined with anti-HBs immunoglobulins in patients transplanted for HBV related cirrhosis. Hepatology 2008; 48: 4584A.